ISPOR Europe 2025 Home
  • About
    • Registration Information
    • News Center
  • Program
    • Program
    • Plenary Sessions
    • Posters
    • Student Program
    • Learning Formats
    • Program Committee
    • Digital Conference Pass
  • Exhibits & Sponsorship
    • Sponsors
    • Media Partners
    • Exhibitor Directory
  • Photo Gallery
  • Award Winners
large-circle

ISPOR Europe 2025

9 - 12 November

  • Home
  • Events
  • Past Conferences
  • ISPOR Europe 2025
  • Program
  • Program
  • Session
  • Plenary Session: RWE in European Healthcare Decision Making—What's in It for Patients?

    Sep 22, 2025, 16:24
  • US-Centric Drug Policies: How National Interests Are Reshaping Global Innovation and Access

    Sep 22, 2025, 16:24
  • Science at PACE? A Multistakeholder Developed Framework for Accelerated Patient Access to Cancer Care

    Sep 22, 2025, 16:24
  • Handling Transitions Between Child and Adult HRQoL in Economic Evaluation

    Sep 22, 2025, 16:24
  • Embedding the Patient Voice Within EU HTA: How Can We Balance Inclusivity, Representativeness, and Scientific Rigor?

    Sep 22, 2025, 16:24
  • Battle of the Bots: Navigating the Landscape of AI-Enabled Systematic Literature Review Platforms

    Sep 22, 2025, 16:24
  • Innovation and Environmental Sustainability in Healthcare: A Multistakeholder Responsibility

    Sep 22, 2025, 16:24
  • Lost in a Labyrinth: EMA and HTA Create Confusion Around Patient-Centered Evidence Requirements in Europe

    Sep 22, 2025, 16:24
  • Methodological Developments in Indirect Treatment Comparisons and Network-Meta-Analyses

    Sep 22, 2025, 16:24
  • The Variable Thresholds Issue: A Necessary Tool or a Misguided Obsession?

    Sep 22, 2025, 16:24
  • Addressing the Socioeconomic Burden and Policy Barriers in Rare Diseases

    Sep 22, 2025, 16:24
  • Europe at Crossroads: Can It Compete With Other Regions for Healthcare Innovation?

    Sep 22, 2025, 16:24
  • Rethinking Access Frameworks for the Next Generation of Multi-Indications/I&I Therapies

    Sep 22, 2025, 16:24
  • Traditional And Emerging Methods for Including Caregiver’s Health-Related Quality of Life in Economic Evaluation: Can We Reconcile Modeling Assumptions With Caregivers’ Experiences?

    Sep 22, 2025, 16:24
  • Beyond the QALY: Alternatives in the US and Implications for EU

    Sep 22, 2025, 16:24
  • Taking a Timeout to Understand Innovations in Survival Modeling: A Practical and Open Discussion of Time-Varying Network Meta-Analyses (NMA) Informing Cost-Effectiveness Models (CEM) and Health Technology Assessments (HTA)

    Sep 22, 2025, 16:24
  • Cost-Effectiveness Modeling of Gene Therapies: Challenges and Solutions

    Sep 22, 2025, 16:24
  • Measuring Health-Related Quality of Life Across the Lifespan

    Sep 22, 2025, 16:24
  • Survival Analysis in the Era of Generative AI

    Sep 22, 2025, 16:24
  • Mind the Gaps: Managing Missing PRO Data in the Era of JCA for HTA Submissions

    Sep 22, 2025, 16:24
  • 1
  • 2
  • 3
  • 4 (current)
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Quick Links

  • About ISPOR
  • Media Center
  • Exhibits & Sponsorships
  • Contact Us
Policies & Legal

  • Antitrust Compliance
  • Code of Ethics
  • Diversity Policy
  • Funding Statement
  • Legal Disclaimer
  • Privacy Policy

Subscribe

Join ISPOR


ISPOR–The Professional Society for
Health Economics and Outcomes Research

Copyright © 2018 ISPOR. All rights reserved.

International Society for Pharmacoeconomics and Outcomes Research, Inc

Website Design & Development by Matrix Group